ArticleBMC infectious diseases2026
A national surveillance study on five-year trends in AMR of E. coli from urine samples in Ethiopia.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
40 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAntimicrobial resistance has become a global public health threat putting the health of millions in danger. Therefore, it is imperative to monitor the trends of resistant bacterial pathogens to better inform public health policies aiming at containing the spread of antimicrobial resistance.
objectiveThis study aimed to assess the prevalence and trends of E. coli resistance from 2020 to 2024 among patients suspected of urinary tract infection in Ethiopia.
methodsFor this study, five years data (2020–2024) from 16 laboratory-based AMR surveillance system sentinel sites were captured by WHONET software and analyzed using R programming language. The data included 4696 E. coli isolates from urine specimens. Descriptive statistics were used to assess the prevalence of antimicrobial resistance and its distribution. Correspondence analysis was used to demonstrate the antimicrobial resistance profile by visualizing the E. coli resistance levels to antibiotics. Furthermore, the Cochran Armitage trend test was employed to test the null hypothesis of no linear trend in antimicrobial resistance against the alternative of a linear trend.
resultsThe majority of patients (n = 2353, 58%) with isolates (n = 2711, 57.7%) were females and 1703 (42%) of patients with 1985 (42.3%) isolates were males. Among 16 sentinel sites, Tikur Anbessa Specialized Hospital and St. Paul’s Hospital contributed the highest numbers of E. coli isolates. Ampicillin, Cefazolin, Cefotaxime, Cefuroxime, and Trimethoprim/Sulfamethoxazole were among a high burden of E. coli resistance rates exceeding 70%, whereas Imipenem, Meropenem, Nitrofurantoin, Amikacin, and Gentamicin exhibited E. coli resistance rates below 30% across 2020 to 2024.
conclusionThe study findings revealed that a high burden and increasing trends of antimicrobial resistance among E.coli isolates from urine samples. These results highlight a critical need to strengthen the national AMR surveillance systems and antimicrobial stewardship programs to help control the growing antimicrobial resistance in the country.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.